

Joseph Cheriyan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/919368/publications.pdf>

Version: 2024-02-01

89
papers

2,299
citations

236925

25
h-index

223800

46
g-index

96
all docs

96
docs citations

96
times ranked

3654
citing authors

#	ARTICLE	IF	CITATIONS
1	Regulatory T-Cell Response to Low-Dose Interleukin-2 in Ischemic Heart Disease. , 2022, 1, .		12
2	Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study. BMC Cardiovascular Disorders, 2022, 22, 49.	1.7	14
3	Niclosamideâ€”A promising treatment for COVIDâ€”19. British Journal of Pharmacology, 2022, 179, 3250-3267.	5.4	31
4	Endothelin-1 is increased in the plasma of patients hospitalised with Covid-19. Journal of Molecular and Cellular Cardiology, 2022, 167, 92-96.	1.9	19
5	Short physical performance battery as a practical tool to assess mortality risk in chronic obstructive pulmonary disease. Age and Ageing, 2021, 50, 795-801.	1.6	12
6	Baricitinib set to join the Covid-19 therapeutic arsenal?. Rheumatology, 2021, 60, 1585-1587.	1.9	7
7	Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease (INTENSITY-HIGH): protocol and study rationale for a randomised, open label, parallel group, mechanistic study. BMJ Open, 2021, 11, e037457.	1.9	4
8	Quantitative ¹⁸ F-fluorodeoxyglucose positron emission tomography/computed tomography to assess pulmonary inflammation in COPD. ERJ Open Research, 2021, 7, 00699-2020.	2.6	2
9	Mechanisms Underlying Vascular Endothelial Growth Factor Receptor Inhibitionâ€”Induced Hypertension. Hypertension, 2021, 77, 1591-1599.	2.7	13
10	THE EFFECTS OF ALIROCUMAB VERSUS EZETIMIBE ON TOP OF STATINS ON VASCULAR INFLAMMATION AND FUNCTION. Journal of the American College of Cardiology, 2021, 77, 159.	2.8	8
11	Characteristics of patients with heart failure with preserved ejection fraction in primary care: a cross-sectional analysis. BJGP Open, 2021, 5, BJGPO.2021.0094.	1.8	7
12	Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19. Pulmonary Pharmacology and Therapeutics, 2021, 69, 102035.	2.6	9
13	Diagnosis of patients with heart failure with preserved ejection fraction in primary care: cohort study. ESC Heart Failure, 2021, 8, 4562-4571.	3.1	2
14	Innate Lymphoid Cells Promote Recovery of Ventricular Function After Myocardial Infarction. Journal of the American College of Cardiology, 2021, 78, 1127-1142.	2.8	27
15	mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): A structured summary of a study protocol for a randomized controlled trial. Trials, 2020, 21, 690.	1.6	14
16	Advances in PET to assess pulmonary inflammation: A systematic review. European Journal of Radiology, 2020, 130, 109182.	2.6	10
17	Consensus Recommendations on the Use of 18F-FDG PET/CT in Lung Disease. Journal of Nuclear Medicine, 2020, 61, 1701-1707.	5.0	8
18	Left atrial mechanics and aortic stiffness following high intensity interval training: a randomised controlled study. European Journal of Applied Physiology, 2020, 120, 1855-1864.	2.5	5

#	ARTICLE	IF	CITATIONS
19	Repurposed immunomodulatory drugs for Covid-19 in pre-ICU patients - multi-Arm Therapeutic study in pre-ICU patients admitted with Covid-19 – Repurposed Drugs (TACTIC-R): A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2020, 21, 626.	1.6	32
20	ChemoPROphyLaxIs with hydroxychloroquine For covid-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2020, 21, 604.	1.6	2
21	Risk assessment for hospital admission in patients with COPD; a multi-centre UK prospective observational study. <i>PLoS ONE</i> , 2020, 15, e0228940.	2.5	13
22	Cardiovascular risk prediction using physical performance measures in COPD: results from a multicentre observational study. <i>BMJ Open</i> , 2020, 10, e038360.	1.9	8
23	The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting October 2019: Impending Change, Innovation, and Future Challenges. <i>Frontiers in Pharmacology</i> , 2020, 11, 580560.	3.5	3
24	Investigating the lowest threshold of vascular benefits from LDL cholesterol lowering with a PCSK9 mAb inhibitor (alirocumab) in healthy volunteers – a mechanistic physiological study (INTENSITY-LOW): protocol and study rationale. <i>Journal of Drug Assessment</i> , 2019, 8, 167-174.	2.2	1
25	Non-invasive measurements of arterial function: What? When? Why should we use them?. <i>Heart</i> , 2019, 105, heartjnl-2018-312970.	2.9	6
26	Development and validation of an LC-MS/MS method for detection and quantification of in vivo derived metabolites of [Pyr1]apelin-13 in humans. <i>Scientific Reports</i> , 2019, 9, 19934.	3.3	14
27	Anti-IL-7 receptor α monoclonal antibody (GSK2618960) in healthy subjects – a randomized, double-blind, placebo-controlled study. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 304-315.	2.4	36
28	Clinical Pharmacokinetics, Safety, and Tolerability of a Novel, First-in-Class TRPV4 Ion Channel Inhibitor, GSK2798745, in Healthy and Heart Failure Subjects. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 335-342.	2.2	88
29	Reproducibility of compartmental modelling of 18F-FDG PET/CT to evaluate lung inflammation. <i>EJNMMI Physics</i> , 2019, 6, 26.	2.7	4
30	Fibrinogen does not relate to cardiovascular or muscle manifestations in COPD: cross-sectional data from the ERICA study. <i>Thorax</i> , 2018, 73, 1182-1185.	5.6	9
31	Surrogate Markers of Cardiovascular Risk and Chronic Obstructive Pulmonary Disease. <i>Hypertension</i> , 2018, 71, 499-506.	2.7	29
32	The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting 2018: Brexit and Other Challenges in Early Phase Drug Development. <i>Frontiers in Pharmacology</i> , 2018, 9, 1301.	3.5	2
33	P29 MECHANISMS OF VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITION INDUCED HYPERTENSION. <i>Artery Research</i> , 2018, 24, 87.	0.6	0
34	GLP-1 Is a Coronary Artery Vasodilator in Humans. <i>Journal of the American Heart Association</i> , 2018, 7, e010321.	3.7	16
35	Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase I/II clinical trial. <i>BMJ Open</i> , 2018, 8, e022452.	1.9	83
36	A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: The comparison of Optimal Hypertension Regimens; part of the Ancestry Informative Markers in Hypertension program – AIM-HY INFORM trial. <i>American Heart Journal</i> , 2018, 204, 102-108.	2.7	11

#	ARTICLE	IF	CITATIONS
37	Vascular inflammation and aortic stiffness: potential mechanisms of increased vascular risk in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2018, 19, 100.	3.6	23
38	The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: A randomised double-blind placebo-controlled trial. <i>PLoS ONE</i> , 2018, 13, e0194197.	2.5	23
39	Quantification of Lung PET Images: Challenges and Opportunities. <i>Journal of Nuclear Medicine</i> , 2017, 58, 201-207.	5.0	55
40	Quantitative analysis of dynamic 18F-FDG PET/CT for measurement of lung inflammation. <i>EJNMMI Research</i> , 2017, 7, 47.	2.5	23
41	Mechanisms of Vascular Dysfunction in COPD and Effects of a Novel Soluble Epoxide Hydrolase Inhibitor in Smokers. <i>Chest</i> , 2017, 151, 555-563.	0.8	62
42	[Pyr1]Apelin-13(1-12) Is a Biologically Active ACE2 Metabolite of the Endogenous Cardiovascular Peptide [Pyr1]Apelin-13. <i>Frontiers in Neuroscience</i> , 2017, 11, 92.	2.8	46
43	Late Breaking Abstract - Co-morbid disease clusters in chronic obstructive pulmonary disease: the ERICA study. , 2017, , .		0
44	Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 971-979.	2.4	122
45	12.6 THE ROLE OF NEURONAL NITRIC OXIDE SYNTHASE IN YOUNG ADULTS. <i>Artery Research</i> , 2016, 16, 78.	0.6	0
46	The Role of the Autonomic Nervous System in the Regulation of Aortic Stiffness. <i>Hypertension</i> , 2016, 68, 1290-1297.	2.7	44
47	Tetrahydrobiopterin Supplementation Improves Endothelial Function But Does Not Alter Aortic Stiffness in Patients With Rheumatoid Arthritis. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	20
48	A functional imaging study to investigate the relationship between pulmonary inflammation and systemic inflammation in COPD patients. , 2016, , .		0
49	A functional imaging study to evaluate aortic inflammation in OSA subjects. , 2016, , .		0
50	The role of epoxyeicosatrienoic acids in the cardiovascular system. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 28-44.	2.4	57
51	S124...The BODE Index is an independent determinant of arterial stiffness in Chronic Obstructive Pulmonary Disease (COPD): Abstract S124 Table 1. <i>Thorax</i> , 2015, 70, A70.2-A71.	5.6	1
52	Comparison of analysis approaches for multi-level vascular imaging data. <i>Trials</i> , 2015, 16, .	1.6	0
53	1.6 THE BODE INDEX PROGNOSTIC SCORE IS AN INDEPENDENT DETERMINANT OF ARTERIAL STIFFNESS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). <i>Artery Research</i> , 2015, 12, 40.	0.6	0
54	P7.14 SERUM INFLAMMATORY MARKERS ARE POOR PREDICTORS OF VASCULAR INFLAMMATION AND VASCULAR INFLAMMATION DOES NOT DETERMINE AORTIC STIFFNESS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). <i>Artery Research</i> , 2015, 12, 33.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Design, Characterization, and First-In-Human Study of the Vascular Actions of a Novel Biased Apelin Receptor Agonist. <i>Hypertension</i> , 2015, 65, 834-840.	2.7	131
56	Safety and pharmacology of a soluble epoxide hydrolase inhibitor. , 2015, , .		1
57	Abstract 18188: Chronic Obstructive Pulmonary Disease (COPD) and Alpha-1 Antitrypsin Deficiency (A1ATD) are Associated With Increased Aortic Inflammation and Stiffness. <i>Circulation</i> , 2015, 132, .	1.6	2
58	Effects of Oral Lycopene Supplementation on Vascular Function in Patients with Cardiovascular Disease and Healthy Volunteers: A Randomised Controlled Trial. <i>PLoS ONE</i> , 2014, 9, e99070.	2.5	101
59	Therapeutic Potential of p38 MAP Kinase Inhibition in the Management of Cardiovascular Disease. <i>American Journal of Cardiovascular Drugs</i> , 2014, 14, 155-165.	2.2	76
60	Value of haemodynamic profiling to the response of antihypertensive therapy. <i>Artery Research</i> , 2014, 8, 189.	0.6	3
61	Evaluation of losmapimod in patients with chronic obstructive pulmonary disease (COPD) with systemic inflammation stratified using fibrinogen (â€˜EVOLUTIONâ€™): Rationale and protocol. <i>Artery Research</i> , 2014, 8, 24.	0.6	9
62	Safety, tolerability, pharmacokinetics and pharmacodynamics of losmapimod following a single intravenous or oral dose in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 99-106.	2.4	24
63	Response to Letter Regarding Article, â€œAntiâ€˜Tumor Necrosis Factor-Î± Therapy Reduces Aortic Inflammation and Stiffness in Patients With Rheumatoid Arthritisâ€• <i>Circulation</i> , 2013, 128, e11.	1.6	1
64	Evaluation of the Vicorder, a novel cuff-based device for the noninvasive estimation of central blood pressure. <i>Journal of Hypertension</i> , 2013, 31, 77-85.	0.5	101
65	Anti-Tumor Necrosis Factor-Î± Therapy Reduces Aortic Inflammation and Stiffness in Patients With Rheumatoid Arthritis. <i>Circulation</i> , 2012, 126, 2473-2480.	1.6	196
66	103â€˜.Aortic inflammation is reduced, and parallels changes in aortic stiffness by anti-TNF Î± therapy in rheumatoid arthritis. <i>Heart</i> , 2012, 98, A59.2-A59.	2.9	0
67	P4.03 ORAL LYCOPENE SUPPLEMENTATION IMPROVES ENDOTHELIAL FUNCTION IN PATIENTS WITH CARDIOVASCULAR DISEASE: A RANDOMISED CONTROLLED TRIAL. <i>Artery Research</i> , 2012, 6, 183.	0.6	0
68	Effects of p38 Mitogen-Activated Protein Kinase Inhibition on Vascular and Systemic Inflammation in Patients With Atherosclerosis. <i>JACC: Cardiovascular Imaging</i> , 2012, 5, 911-922.	5.3	123
69	Increased Incidence of Interatrial Block in Younger Adults with Cryptogenic Stroke and Patent Foramen Ovale. <i>Cerebrovascular Diseases Extra</i> , 2011, 1, 36-43.	1.5	31
70	Inhibition of p38 Mitogen-Activated Protein Kinase Improves Nitric Oxideâ€˜Mediated Vasodilatation and Reduces Inflammation in Hypercholesterolemia. <i>Circulation</i> , 2011, 123, 515-523.	1.6	88
71	Simvastatin prevents inflammationâ€˜induced aortic stiffening and endothelial dysfunction. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 799-806.	2.4	30
72	3.2 A COMPARISON OF THE VICORDER APPARATUS WITH SPHYGMOCOR DEVICE FOR THE NON-INVASIVE ASSESSMENT OF AORTIC BLOOD PRESSURE: AN INVASIVE VALIDATION STUDY. <i>Artery Research</i> , 2010, 4, 146.	0.6	1

#	ARTICLE	IF	CITATIONS
73	Primary prevention of CVD: treating hypertension. <i>Clinical Evidence</i> , 2010, 2010, .	0.2	2
74	The effects of urotensin II and urantide on forearm blood flow and systemic haemodynamics in humans. <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 518-523.	2.4	10
75	P1.06 THE ACCURACY OF CENTRAL SYSTOLIC BLOOD PRESSURE DETERMINED FROM THE SECOND SYSTOLIC PEAK OF THE PERIPHERAL PRESSURE WAVEFORM. <i>Artery Research</i> , 2009, 3, 162.	0.6	0
76	The accuracy of central SBP determined from the second systolic peak of the peripheral pressure waveform. <i>Journal of Hypertension</i> , 2009, 27, 1784-1788.	0.5	62
77	Chapter 1 Aetiology and pathophysiology. , 2009, , .		0
78	Chapter 4 Secondary hypertension. , 2009, , .		0
79	Chapter 6 Special populations. , 2009, , .		0
80	Chapter 8 Hypertension in the 21st century. , 2009, , .		0
81	Chapter 3 Specific investigations for secondary hypertension. , 2009, , .		0
82	Chapter 5 Monogenic syndromes. , 2009, , .		0
83	Inducible nitric oxide synthase activity is increased in patients with rheumatoid arthritis and contributes to endothelial dysfunction. <i>International Journal of Cardiology</i> , 2008, 129, 399-405.	1.7	46
84	Approximation Algorithms for Network Design with Metric Costs. <i>SIAM Journal on Discrete Mathematics</i> , 2007, 21, 612-636.	0.8	29
85	Role of increased aortic stiffness in the pathogenesis of heart failure. <i>Current Heart Failure Reports</i> , 2007, 4, 121-126.	3.3	8
86	An $O(V \log V)$ algorithm for ear decompositions of matching-covered graphs. <i>ACM Transactions on Algorithms</i> , 2005, 1, 324-337.	1.0	6
87	Aldehyde Dehydrogenase 2 Plays a Role in the Bioactivation of Nitroglycerin in Humans. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 1891-1895.	2.4	82
88	An Approximation Algorithm for the Minimum-Cost k -Vertex Connected Subgraph. <i>SIAM Journal on Computing</i> , 2003, 32, 1050-1055.	1.0	69
89	Randomized $O(M(V))$ Algorithms for Problems in Matching Theory. <i>SIAM Journal on Computing</i> , 1997, 26, 1635-1655.	1.0	28